旨在超越时间范围内的最佳血糖控制:使用不同治疗方式治疗1型糖尿病儿童和青少年的时间范围内:作为一种新的CGM指标。

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes technology & therapeutics Pub Date : 2024-03-01 DOI:10.1089/dia.2023.0373
Stefano Passanisi, Claudia Piona, Giuseppina Salzano, Marco Marigliano, Bruno Bombaci, Anita Morandi, Angela Alibrandi, Claudio Maffeis, Fortunato Lombardo
{"title":"旨在超越时间范围内的最佳血糖控制:使用不同治疗方式治疗1型糖尿病儿童和青少年的时间范围内:作为一种新的CGM指标。","authors":"Stefano Passanisi, Claudia Piona, Giuseppina Salzano, Marco Marigliano, Bruno Bombaci, Anita Morandi, Angela Alibrandi, Claudio Maffeis, Fortunato Lombardo","doi":"10.1089/dia.2023.0373","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> To evaluate time in tight range (TITR) 70-140 mg/dL (3.9-7.8 mmol/L), its correlation with standard continuous glucose monitoring (CGM) metrics and the clinical variables that possibly have a substantial impact on its value, in a large cohort of pediatric subjects using different treatment strategies. <b><i>Materials and Methods:</i></b> A total of 854 children and adolescents with type 1 diabetes were consecutively recruited in this real world, dual center, cross-sectional study. Participants were categorized into four treatment groups (multiple daily injections [MDI] + real-time CGM, MDI + intermittently scanned CGM, sensor augmented pump, and hybrid closed loop [HCL]). Demographical and clinical data, including CGM data, were collected and analyzed. <b><i>Results:</i></b> The overall study population exhibited an average TITR of 36.4% ± 12.8%. HCL users showed higher TITR levels compared to the other treatment groups (<i>P</i> < 0.001). A time in range (TIR) cut-off value of 71.9% identified subjects achieving a TITR ≥50% (area under curve [AUC] 0.98; 95% confidence interval 0.97-0.99, <i>P</i> < 0.001), and a strong positive correlation between these two metrics was observed (<i>r</i> = 0.95, <i>P</i> < 0.001). An increase in TIR of 1% was associated with 1.84 (<i>R</i><sup>2</sup> Nagelkerke = 0.35, <i>P</i> < 0.001) increased likelihood of achieving TITR ≥50%. Use of HCL systems (<i>B</i> = 7.78; <i>P</i> < 0.001), disease duration (<i>B</i> = -0.26, <i>P</i> = 0.006), coefficient of variation (<i>B</i> = -0.30, <i>P</i> = 0.004), and glycated hemoglobin (<i>B</i> = -8.82; <i>P</i> < 0.001) emerged as significant predictors of TITR levels. <b><i>Conclusions:</i></b> Our study highlights that most children and adolescents with type 1 diabetes present TITR levels below 50%, except those using HCL. Tailored interventions and strategies should be implemented to increase TITR.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"161-166"},"PeriodicalIF":5.7000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities.\",\"authors\":\"Stefano Passanisi, Claudia Piona, Giuseppina Salzano, Marco Marigliano, Bruno Bombaci, Anita Morandi, Angela Alibrandi, Claudio Maffeis, Fortunato Lombardo\",\"doi\":\"10.1089/dia.2023.0373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Introduction:</i></b> To evaluate time in tight range (TITR) 70-140 mg/dL (3.9-7.8 mmol/L), its correlation with standard continuous glucose monitoring (CGM) metrics and the clinical variables that possibly have a substantial impact on its value, in a large cohort of pediatric subjects using different treatment strategies. <b><i>Materials and Methods:</i></b> A total of 854 children and adolescents with type 1 diabetes were consecutively recruited in this real world, dual center, cross-sectional study. Participants were categorized into four treatment groups (multiple daily injections [MDI] + real-time CGM, MDI + intermittently scanned CGM, sensor augmented pump, and hybrid closed loop [HCL]). Demographical and clinical data, including CGM data, were collected and analyzed. <b><i>Results:</i></b> The overall study population exhibited an average TITR of 36.4% ± 12.8%. HCL users showed higher TITR levels compared to the other treatment groups (<i>P</i> < 0.001). A time in range (TIR) cut-off value of 71.9% identified subjects achieving a TITR ≥50% (area under curve [AUC] 0.98; 95% confidence interval 0.97-0.99, <i>P</i> < 0.001), and a strong positive correlation between these two metrics was observed (<i>r</i> = 0.95, <i>P</i> < 0.001). An increase in TIR of 1% was associated with 1.84 (<i>R</i><sup>2</sup> Nagelkerke = 0.35, <i>P</i> < 0.001) increased likelihood of achieving TITR ≥50%. Use of HCL systems (<i>B</i> = 7.78; <i>P</i> < 0.001), disease duration (<i>B</i> = -0.26, <i>P</i> = 0.006), coefficient of variation (<i>B</i> = -0.30, <i>P</i> = 0.004), and glycated hemoglobin (<i>B</i> = -8.82; <i>P</i> < 0.001) emerged as significant predictors of TITR levels. <b><i>Conclusions:</i></b> Our study highlights that most children and adolescents with type 1 diabetes present TITR levels below 50%, except those using HCL. Tailored interventions and strategies should be implemented to increase TITR.</p>\",\"PeriodicalId\":11159,\"journal\":{\"name\":\"Diabetes technology & therapeutics\",\"volume\":\" \",\"pages\":\"161-166\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes technology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/dia.2023.0373\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2023.0373","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

引言:在使用不同治疗策略的大型儿科受试者队列中,评估紧范围(TITR)70-140 mg/dL(3.9-7.8 mmol/L)的时间、其与标准连续血糖监测(CGM)指标的相关性以及可能对其价值产生重大影响的临床变量。材料和方法:在这项现实世界的双中心横断面研究中,共连续招募了854名患有1型糖尿病的儿童和青少年。参与者被分为四个治疗组(每天多次注射+实时CGM、每天多次注射+间歇性扫描CGM、传感器增强泵和混合闭环(HCL))。收集并分析人口统计学和临床数据,包括CGM数据。结果:总体研究人群的平均TITR为36.4±12.8%。与其他治疗组相比,HCL使用者的TITR水平更高(P结论:我们的研究强调,除使用HCL的儿童和青少年外,大多数1型糖尿病儿童和青少年的TITR平均低于50%。应实施量身定制的干预措施和策略来提高TITR。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities.

Introduction: To evaluate time in tight range (TITR) 70-140 mg/dL (3.9-7.8 mmol/L), its correlation with standard continuous glucose monitoring (CGM) metrics and the clinical variables that possibly have a substantial impact on its value, in a large cohort of pediatric subjects using different treatment strategies. Materials and Methods: A total of 854 children and adolescents with type 1 diabetes were consecutively recruited in this real world, dual center, cross-sectional study. Participants were categorized into four treatment groups (multiple daily injections [MDI] + real-time CGM, MDI + intermittently scanned CGM, sensor augmented pump, and hybrid closed loop [HCL]). Demographical and clinical data, including CGM data, were collected and analyzed. Results: The overall study population exhibited an average TITR of 36.4% ± 12.8%. HCL users showed higher TITR levels compared to the other treatment groups (P < 0.001). A time in range (TIR) cut-off value of 71.9% identified subjects achieving a TITR ≥50% (area under curve [AUC] 0.98; 95% confidence interval 0.97-0.99, P < 0.001), and a strong positive correlation between these two metrics was observed (r = 0.95, P < 0.001). An increase in TIR of 1% was associated with 1.84 (R2 Nagelkerke = 0.35, P < 0.001) increased likelihood of achieving TITR ≥50%. Use of HCL systems (B = 7.78; P < 0.001), disease duration (B = -0.26, P = 0.006), coefficient of variation (B = -0.30, P = 0.004), and glycated hemoglobin (B = -8.82; P < 0.001) emerged as significant predictors of TITR levels. Conclusions: Our study highlights that most children and adolescents with type 1 diabetes present TITR levels below 50%, except those using HCL. Tailored interventions and strategies should be implemented to increase TITR.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
期刊最新文献
Impact of Continuous Glucose Monitoring Versus Blood Glucose Monitoring to Support a Carbohydrate-Restricted Nutrition Intervention in People with Type 2 Diabetes. Comparison of Computational Statistical Packages for the Analysis of Continuous Glucose Monitoring Data with a Reference Software, "Ambulatory Glucose Profile," in Type 1 Diabetes. Effect of Interrupting Prolonged Sitting with Frequent Activity Breaks on Postprandial Glycemia and Insulin Sensitivity in Adults with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy: A Randomized Crossover Pilot Trial. Evaluation of an Automated Priming Bolus for Improving Prandial Glucose Control in Full Closed Loop Delivery. Safe Options for the Treatment of Mothers and Babies with Pregestational Diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1